Wegovy vs Ozempic — What's the Difference and Which Is Better for Weight Loss?

Wegovy vs Ozempic explained: both are semaglutide, but they're approved for different things. Here's what the research says about dosing, weight loss results, side effects, and which is right for you.

If you’ve been researching GLP-1 medications for weight loss, you’ve almost certainly run into a version of this question: What’s the difference between Wegovy and Ozempic? Both seem to be semaglutide. Both come from the same manufacturer. Both are injected weekly. And yet they have different names, different prices, and different FDA approvals. It’s legitimately confusing — and the confusion matters, because the distinction affects your dosing, your insurance coverage, your weight loss trajectory, and how you should be managing side effects.

Here’s a clear, evidence-based breakdown of everything you need to know about Wegovy vs Ozempic.

The Core Fact: Same Drug, Different Doses and Approvals

The most important thing to understand about Wegovy and Ozempic is this: they are both semaglutide. The same active molecule. Made by the same company (Novo Nordisk). Delivered via the same type of weekly subcutaneous injection.

The difference is in why they’re prescribed and how high the dose goes.

  • Ozempic is FDA-approved for type 2 diabetes management. It’s designed to help control blood sugar, and it’s prescribed at doses of 0.5 mg, 1 mg, and 2 mg weekly.
  • Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. Its dose escalates up to 2.4 mg weekly — the highest available dose of semaglutide.

That extra dose is significant. The higher the semaglutide dose, the greater the appetite suppression and weight loss — which is exactly why Wegovy was developed and trialed specifically for obesity treatment.

Why Doctors Sometimes Prescribe Ozempic “Off-Label” for Weight Loss

You may already know that many people use Ozempic specifically for weight loss, even though that’s not its FDA-approved indication. This is called off-label prescribing, and it’s legal and common in medicine.

For years, Ozempic was prescribed off-label for weight management because Wegovy wasn’t available — supply shortages, insurance coverage gaps, and formulary issues pushed patients and prescribers toward Ozempic as a practical alternative. In many cases, patients achieved significant weight loss on Ozempic doses (particularly the 1 mg and 2 mg options), even without reaching the 2.4 mg ceiling that Wegovy offers.

The clinical reality is that semaglutide at any dose produces meaningful appetite suppression and weight reduction. But when weight loss is the primary goal, Wegovy’s higher dose ceiling gives it an edge — and the clinical trial data backs that up clearly.

Weight Loss Results: What the Clinical Trials Show

For Wegovy (semaglutide 2.4 mg): The STEP 1 trial — the pivotal study behind Wegovy’s FDA approval — found that participants lost an average of 14.9% of total body weight over 68 weeks. For someone starting at 250 pounds, that’s roughly 37 pounds. Even more striking: one in three participants lost more than 20% of their starting weight.

For Ozempic (semaglutide up to 2 mg): Off-label weight loss studies and real-world data show meaningful results at the 1–2 mg doses, typically in the range of 8–12% body weight loss over similar timeframes. That’s genuinely significant, but it’s measurably less than what the full Wegovy dose produces in most patients.

The takeaway: if you’re using semaglutide specifically to lose weight, Wegovy’s higher maximum dose is designed to get you further. The STEP trials consistently showed dose-dependent weight loss — meaning more semaglutide, more weight lost, up to the studied ceiling of 2.4 mg.

Side Effects: Essentially the Same Profile

Because Wegovy and Ozempic are the same molecule, they share an almost identical side effect profile. The main differences come from the higher Wegovy dose, which can make certain side effects more pronounced — particularly during the escalation phase.

Most common side effects on both:

  • Nausea — very common during dose escalation, typically improving over 4–8 weeks per dose level
  • Constipation — one of the most persistent and underreported GLP-1 side effects, affecting many patients throughout treatment
  • Vomiting and diarrhea — usually dose-dependent and temporary
  • Reduced appetite — the intended effect, though occasionally more extreme than desired
  • Fatigue — especially in the early weeks of a new dose

Is Wegovy worse for side effects? At higher doses, yes — modestly. Patients escalating to 2.4 mg Wegovy often experience more nausea and GI discomfort than those staying at 1 mg or 2 mg Ozempic. Slowing the escalation schedule is a common clinical strategy to manage this.

Constipation deserves its own mention. GLP-1 medications work partly by slowing gastric emptying — that’s part of how they reduce appetite. But the same mechanism slows the entire GI tract, making constipation one of the most persistent side effects across all semaglutide doses. It’s not just uncomfortable; it’s one of the leading reasons patients consider stopping their medication before reaching their goals.

Managing constipation proactively — through targeted fiber intake, hydration, and gut motility strategies — is one of the most impactful things you can do for long-term success on either Wegovy or Ozempic.

Managing GLP-1 constipation or navigating the full side effect picture? Our GLP-1 Constipation Relief Guide ($21.97) gives you the complete clinical strategy — from fiber timing to safe supplements to what to do when over-the-counter options aren’t enough. And our Starter Bundle ($39.99) pairs it with two more essential guides at a significant discount, giving you a complete toolkit for thriving on semaglutide.

Insurance and Cost: A Very Real Practical Difference

For many patients, the Wegovy vs Ozempic decision isn’t primarily medical — it’s financial and logistical.

Ozempic has been on the market longer and has broader insurance coverage for type 2 diabetes. Many commercial plans and Medicare Part D plans cover it with relatively manageable copays for qualifying diabetic patients.

Wegovy, despite its obesity indication, has historically faced more inconsistent insurance coverage. The Treat and Reduce Obesity Act and expanding commercial coverage are improving access, but cost remains a barrier for some. Without insurance, both medications carry high list prices — though manufacturer savings cards can substantially reduce out-of-pocket costs for eligible patients.

Compounded semaglutide was a third option during shortage periods, but the FDA has moved to limit it as the shortage has eased. If you’re on compounded semaglutide, it’s worth discussing the transition to an FDA-approved branded product with your provider.

The bottom line on cost: your prescriber, pharmacist, and insurance coordinator are the right people to work through the specifics. The clinical and research team at FlowWell can help you understand the medications — but coverage decisions are highly individual.

Which Should You Ask Your Doctor About?

Neither Wegovy nor Ozempic is universally “better” — the right choice depends on your individual health profile, goals, and coverage situation. Here’s a general framework:

Wegovy may be the more appropriate conversation if:

  • Your primary goal is weight loss and you don’t have a type 2 diabetes diagnosis
  • You want to reach the highest available semaglutide dose (2.4 mg)
  • Your insurance covers Wegovy for obesity treatment
  • You’re working with an obesity medicine specialist who can access the full labeled dose

Ozempic may be the right starting point if:

  • You have type 2 diabetes and weight management is a secondary goal
  • Ozempic is better covered on your plan
  • You’re trying semaglutide for the first time and want to assess tolerability at lower doses before considering the higher Wegovy doses
  • Your prescriber recommends it based on your full clinical picture

For both medications, preparation matters enormously. The patients who see the best results are the ones who understand what to expect at each dose stage, who manage their nutrition and fiber intake proactively, and who have a strategy for getting through the inevitable uncomfortable weeks of dose escalation.

What Else You Should Know: Cardiovascular Benefits and Obesity as a Disease

One development that applies equally to both Wegovy and Ozempic: semaglutide has now demonstrated meaningful cardiovascular benefits beyond just weight loss. The SELECT trial — a landmark 2023 study — showed that semaglutide significantly reduced the risk of major adverse cardiovascular events in people with obesity and established cardiovascular disease, even without diabetes.

This reframes the conversation around GLP-1 therapy. For many patients, this isn’t just about weight — it’s about reducing long-term cardiovascular risk, improving metabolic health, and treating obesity as the complex chronic condition it is, rather than a lifestyle choice.

Want a deeper understanding of GLP-1 medications and obesity treatment? Our Obesity & GLP-1 Guide ($19.99) covers the science of obesity pharmacotherapy, what the latest research shows about GLP-1 mechanisms, and how to be an informed, empowered patient. It’s built for people who want to understand why these medications work — not just that they do.

The Bottom Line

Wegovy and Ozempic are the same drug — semaglutide — but they’re designed for different primary purposes and approved at different dose ceilings. Wegovy’s 2.4 mg maximum dose produces greater average weight loss in clinical trials. Ozempic remains highly effective for both blood sugar control and meaningful weight reduction at its approved doses. For many patients, the practical differences come down to insurance coverage and prescribing context.

What’s consistent across both: they work best when you’re prepared. Managing the side effect journey, optimizing your nutrition and fiber strategy, and understanding what each phase of treatment looks like — that’s where outcomes are actually built.

FlowWell’s guides are designed to give you exactly that foundation, whether you’re on week one of your first dose or troubleshooting a plateau after six months. Explore our Starter Bundle to get three essential GLP-1 guides in one — and start your treatment journey with confidence.